Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Juvaris BioTherapeutics Inc.

Latest From Juvaris BioTherapeutics Inc.

Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn

Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.

BioPharmaceutical Deals

Giant leap for MannKind's Affrezza as Colby takes immunotherapies off back burner

MannKind stands to gain up to $140 million in upfront and milestone payments plus royalties under a license agreement with Colby Pharmaceutical, which will take over development of novel MKC1106 immunotherapies, allowing MannKind to move another oncology asset forward while remaining focused on Phase III development of its inhaled diabetes drug Affrezza.

Metabolic Disorders Cancer

Universal flu vaccine BiondVax goes robustly beyond first phase II trial

The prospects of a "universal" flu vaccine becoming a pharmaceutical reality have received a boost with positive results from the first Phase II trial of an investigational product from the Israeli biotech company BiondVax Pharmaceuticals.

Infectious Diseases Israel

Novartis champions pre-pandemic vaccination programme

One year on since the start of the swine flu outbreak, the cracks in our pandemic preparation strategy have become apparent. One solution, suggests Novartis's vice-president of influenza strategy Dr Klaus Stöhr, is pre-pandemic vaccination programmes.

Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule